Enzalutamide represents a clinically relevant second-generation androgen receptor antagonist employed for the treatment of metastatic castration-sensitive PCa endowed with significant effect in terms of prolonged survival in CRPC, although patients eventually experience disease progression [31]. Here, AR is linked to posterior cortical atrophy.